Viz.ai, Johns Hopkins collaboration aids enrollment for NIH-funded brain injury trial

Viz.ai announced a collaboration with BIOS Clinical Trials Coordinating Center at Johns Hopkins University to facilitate patient enrollment for the NIH-funded Biomarker and Edema Attenuation in Intracerebral Hemorrhage study.

According to a Viz release, the partnership will give BEACH research teams access to Viz Recruit software, the company’s clinical trial acceleration platform, which expedites enrollment by expanding recruitment access and diversity of patients at trial-eligible hospitals.

“Clinical trial enrollment is often a bottleneck when it comes to developing novel therapies,” Jayme Strauss, chief clinical officer at Viz.ai, said in the release. “Together, with Johns Hopkins, we have an exciting opportunity to increase access to the BEACH trial and help to enhance neurologic recovery and outcomes for patients.”

The BEACH trial is investigating the safety and tolerability of MW189, a small molecule that selectively reduces proinflammatory cytokine overproduction in patients with intracerebral hemorrhage, the release stated.

Viz Recruit will identify individuals with suspected intracerebral hemorrhage, with BEACH trial inclusion volumetric assessment criteria between 10 mL and 60 mL, and notify research team members of potential trial candidates through Viz.ai’s HIPAA-compliant app.

“By incorporating Viz Recruit software into the BEACH trial, we’re enabling more patients with intracerebral hemorrhage to get access to novel treatments like MW189,” Daniel Hanley, MD, co-principal investigator of the BEACH trial at Johns Hopkins, said in the release. “Success for the development of novel treatments like this is dependent upon increased enrollment in clinical trials, which in turn opens the door for larger trials of MW189 in acute CNS injury and age-related dementias.”